Newsletter

April 2018 Scorecard

The April 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar Remember to enter the promo code: […]

0Comments

Sientra Receives FDA Approval on Premarket Approval Supplement

Sientra, Inc. (SIEN) announced on April 18 that it had received FDA approval on its premarket approval (PMA) supplement. The approval allows Sientra to commercialize its OPUS-branded breast implant products manufactured at Vesta’s Wisconsin manufacturing facility. Sientra had been working closely with Vestra over the past two years on manufacturing the OPUS-branded breast implant, which […]

0Comments

Novocure Announces Positive Phase 2 Clinical Trial Results for Mesothelioma Patients

On April 17, Novocure (NVCR) announced positive results from its Phase 2 clinical trial for the treatment of mesothelioma. Patients who received Tumor Treatment Fields in addition to standard chemotherapy treatment experienced improvements in overall survival and progression. Novocure is a global oncology company developing its proprietary technology called Tumor Treating Fields, which use electric […]

0Comments

March 2018 Scorecard

The March 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar Remember to enter the promo code: […]

0Comments

MiMedx Reports Positive Clinical Trial Results of AmnioFix for Plantar Fasciitis

On March 26, MiMedx Group, Inc. (MDXG) reported positive results from its Phase 2B IND clinical trial of AmnioFix. In the clinical trial, patients who received the AmnioFix Injectable treatment for their Plantar Fasciitis had a clinically and statistically significant improvement when compared to the control group. Plantar Fasciitis is the most common cause of […]

0Comments

G1 Therapeutics Reports Positive Clinical Trial Results in Patients Receiving Chemotherapy for Small Cell Lung Cancer

On March 5, G1 Therapeutics, Inc. (GTHX) reported positive topline data from its Phase 2a trial for Trilaciclib in patients receiving chemotherapy for first-line small cell lung cancer. The data from the trial showed clear evidence that Trilaciclib preserved bone marrow and immune system function from damage due to chemotherapy treatment. Trilaciclib would be the […]

0Comments

FDA Accepts Jazz Pharmaceuticals’ NDA for Solriamfetol Treatment in Patients with Narcolepsy and Sleep Apnea

On March 2, Jazz Pharmaceuticals plc (JAZZ) announced that the FDA has accepted the company’s filing of a New Drug Application (NDA) with standard review for market approval of Solriamfetol. The drug is an investigational medicine used for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea (OSA). The company hopes […]

0Comments

February 2018 Scorecard

The February 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar Remember to enter the promo code: […]

0Comments

Sorrento Therapeutics Subsidiary Receives FDA Approval for Non-Opiod Ztlido

On February 28, Sorrento Therapeutics (SRNE) Subsidiary, Scilex, received FDA approval for non-opiod Ztlido. The drug is a lidocaine topical system used to treat pain. Sorrento hopes to have it commercially available to patients later this year.   Rocket Tickers received the news and sent an alert to subscribers at 2:11 pm. The next trade […]

0Comments

June 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December 2017 Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next Close to 5-day Peak 4% Other stats: Number of signals over $10/share 16 […]

0Comments

Latest of Knowledge Center